The Patent Finder

Terms ending in 2029

Eth Zurich

Every in-force patent on Eth Zurich's record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 9,377,463Method for Biomarker and Drug-Target Discovery for Prostate Cancer Diagnosis and Treatment as Well as Biomarker Assays Determined Therewith
In force
 · High confidence
Eth ZurichIn forceHigh confidence
US 10,151,755Method for Biomarker and Drug-Target Discovery for Prostate Cancer Diagnosis and Treatment as Well as Biomarker Assays Determined Therewith
In force
 · High confidence
Eth ZurichIn forceHigh confidence
US 8,148,344Compositions and Methods for Mediating Rnai in Vivo
In force
 · High confidence
Eth ZurichIn forceHigh confidence
US 8,324,366Compositions and Methods for Delivering Rnai Using Lipoproteins
In force
 · High confidence
Eth ZurichIn forceHigh confidence
US 8,388,945Degradable Microcapsules
In force
 · High confidence
Swissgenetics GenossenschaftIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Eth Zurich.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited